Michael Hallek to Antineoplastic Agents
This is a "connection" page, showing publications Michael Hallek has written about Antineoplastic Agents.
Connection Strength
1.311
-
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
Score: 0.252
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
Score: 0.237
-
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
Score: 0.222
-
Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun; 35 Suppl 1:30-32.
Score: 0.217
-
[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]. Dtsch Med Wochenschr. 2018 09; 143(18):1318-1324.
Score: 0.059
-
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018 08 01; 78(15):4270-4281.
Score: 0.058
-
[Which drugs in Hemato-Oncology are Unnecessary or Inappropriate for Use in the Elderly?] Dtsch Med Wochenschr. 2018 02; 143(4):244-252.
Score: 0.057
-
The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. BMC Cancer. 2018 01 10; 18(1):62.
Score: 0.057
-
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 12; 31(12):2833-2837.
Score: 0.055
-
Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Feb; 56(2):285-92.
Score: 0.044
-
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019 11; 104(11):2144-2154.
Score: 0.016
-
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
Score: 0.014
-
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 09; 178(6):949-953.
Score: 0.014
-
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
Score: 0.008